نتائج البحث - "Robert Z. Orlowski"

1

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

المصدر: Kumar, S K, Facon, T, Usmani, S Z, Plesner, T, Orlowski, R Z, Touzeau, C, Basu, S, Bahlis, N J, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Hulin, C, Karlin, L, Preis, M, Broyl, A, Renwick, W, Hansson, M, Krevvata, M, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, C M, Kobos, R & Perrot, A 2020, ' Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) : The Phase 3 Maia Study ', Blood, vol. 136, no. Suppl. 1, pp. 24-26 . https://doi.org/10.1182/blood-2020-134847Test

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Immunology, Daratumumab, Cell Biology, Hematology, Newly diagnosed, medicine.disease, Biochemistry, Transplant ineligible, Internal medicine, medicine, In patient, business, Multiple myeloma, Dexamethasone, Lenalidomide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5896bbe9c1a891d488ec422553d253f1Test
https://doi.org/10.1182/blood-2020-134847Test

2

Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis

المؤلفون: Krina K. Patel, Donna M. Weber, Taha Al-Juhaishi, Elisabet E. Manasanch, Regan Murphy, Qaiser Bashir, Samer A. Srour, Jeremy Ramdial, Gregory P. Kaufman, Hans C. Lee, Robert Z. Orlowski, Chitra Hosing, Sheeba K. Thomas, Uday R. Popat, Richard E. Champlin, Yago Nieto, Muzaffar H. Qazilbash, Mahmoud R. Gaballa, Neeraj Saini

المصدر: Blood. 136:11-13

مصطلحات موضوعية: Cardiac response, Response rate (survey), medicine.medical_specialty, business.industry, Immunology, Small sample, Cell Biology, Hematology, Biochemistry, Nyha class, Peripheral blood, Baseline characteristics, Family medicine, Medicine, In patient, business, Bristol-Myers

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ddc41c501011a8221f58c6a08cee33b4Test
https://doi.org/10.1182/blood-2020-143209Test

3

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

المصدر: Perrot, A, Facon, T, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N J, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M E, Venner, C P, Weisel, K, Mace, J R, Raje, N S, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Liu, K, Fastenau, J, Gries, K S, Ho, K F, Mistry, P, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression : Post Hoc Analyses from MAIA ', Blood, vol. 138, no. Suppl. 1, 4095 . https://doi.org/10.1182/blood-2021-150369Test

مصطلحات موضوعية: medicine.medical_specialty, Post hoc, Relation (database), business.industry, Internal medicine, Immunology, Disease progression, medicine, In patient, Cell Biology, Hematology, business, Biochemistry